Your browser doesn't support javascript.
loading
Spatially mapping the immune landscape of melanoma using imaging mass cytometry.
Moldoveanu, Dan; Ramsay, LeeAnn; Lajoie, Mathieu; Anderson-Trocme, Luke; Lingrand, Marine; Berry, Diana; Perus, Lucas J M; Wei, Yuhong; Moraes, Cleber; Alkallas, Rached; Rajkumar, Shivshankari; Zuo, Dongmei; Dankner, Matthew; Xu, Eric Hongbo; Bertos, Nicholas R; Najafabadi, Hamed S; Gravel, Simon; Costantino, Santiago; Richer, Martin J; Lund, Amanda W; Del Rincon, Sonia V; Spatz, Alan; Miller, Wilson H; Jamal, Rahima; Lapointe, Réjean; Mes-Masson, Anne-Marie; Turcotte, Simon; Petrecca, Kevin; Dumitra, Sinziana; Meguerditchian, Ari-Nareg; Richardson, Keith; Tremblay, Francine; Wang, Beatrice; Chergui, May; Guiot, Marie-Christine; Watters, Kevin; Stagg, John; Quail, Daniela F; Mihalcioiu, Catalin; Meterissian, Sarkis; Watson, Ian R.
Afiliação
  • Moldoveanu D; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Ramsay L; McGill University Health Centre, Montréal, QC, Canada.
  • Lajoie M; Department of Surgery, Division of General Surgery, McGill University, Montréal, QC, Canada.
  • Anderson-Trocme L; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Lingrand M; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Berry D; McGill University Genome Centre, Montréal, QC, Canada.
  • Perus LJM; Department of Human Genetics, McGill University, Montréal, QC, Canada.
  • Wei Y; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Moraes C; Department of Biochemistry, McGill University, Montréal, QC, Canada.
  • Alkallas R; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Rajkumar S; Department of Biochemistry, McGill University, Montréal, QC, Canada.
  • Zuo D; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Dankner M; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Xu EH; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Bertos NR; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Najafabadi HS; McGill University Genome Centre, Montréal, QC, Canada.
  • Gravel S; Department of Human Genetics, McGill University, Montréal, QC, Canada.
  • Costantino S; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Richer MJ; Department of Biochemistry, McGill University, Montréal, QC, Canada.
  • Lund AW; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Del Rincon SV; Rosalind and Morris Goodman Cancer Institute, McGill University, Montréal, QC, Canada.
  • Spatz A; Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • Miller WH; Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • Jamal R; McGill University Genome Centre, Montréal, QC, Canada.
  • Lapointe R; Department of Human Genetics, McGill University, Montréal, QC, Canada.
  • Mes-Masson AM; McGill University Genome Centre, Montréal, QC, Canada.
  • Turcotte S; Department of Human Genetics, McGill University, Montréal, QC, Canada.
  • Petrecca K; Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
  • Dumitra S; Indiana University School of Medicine, Indianapolis, IN, USA.
  • Meguerditchian AN; Ronald O. Perelman Department of Dermatology and Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
  • Richardson K; Jewish General Hospital, McGill University, Montréal, QC, Canada.
  • Tremblay F; Lady Davis Institute for Medical Research, Montréal, QC, Canada.
  • Wang B; McGill University Health Centre, Montréal, QC, Canada.
  • Chergui M; Lady Davis Institute for Medical Research, Montréal, QC, Canada.
  • Guiot MC; McGill University, Montréal, QC, Canada.
  • Watters K; Jewish General Hospital, McGill University, Montréal, QC, Canada.
  • Stagg J; Lady Davis Institute for Medical Research, Montréal, QC, Canada.
  • Quail DF; Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Institut du Cancer de Montréal, Montréal, QC, Canada.
  • Mihalcioiu C; Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Institut du Cancer de Montréal, Montréal, QC, Canada.
  • Meterissian S; Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada.
  • Watson IR; Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) and Institut du Cancer de Montréal, Montréal, QC, Canada.
Sci Immunol ; 7(70): eabi5072, 2022 04.
Article em En | MEDLINE | ID: mdl-35363543
ABSTRACT
Melanoma is an immunogenic cancer with a high response rate to immune checkpoint inhibitors (ICIs). It harbors a high mutation burden compared with other cancers and, as a result, has abundant tumor-infiltrating lymphocytes (TILs) within its microenvironment. However, understanding the complex interplay between the stroma, tumor cells, and distinct TIL subsets remains a substantial challenge in immune oncology. To properly study this interplay, quantifying spatial relationships of multiple cell types within the tumor microenvironment is crucial. To address this, we used cytometry time-of-flight (CyTOF) imaging mass cytometry (IMC) to simultaneously quantify the expression of 35 protein markers, characterizing the microenvironment of 5 benign nevi and 67 melanomas. We profiled more than 220,000 individual cells to identify melanoma, lymphocyte subsets, macrophage/monocyte, and stromal cell populations, allowing for in-depth spatial quantification of the melanoma microenvironment. We found that within pretreatment melanomas, the abundance of proliferating antigen-experienced cytotoxic T cells (CD8+CD45RO+Ki67+) and the proximity of antigen-experienced cytotoxic T cells to melanoma cells were associated with positive response to ICIs. Our study highlights the potential of multiplexed single-cell technology to quantify spatial cell-cell interactions within the tumor microenvironment to understand immune therapy responses.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Melanoma Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Melanoma Idioma: En Ano de publicação: 2022 Tipo de documento: Article